Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 402Rectal Neoplasms 151Colonic Neoplasms 148Pancreatic Neoplasms 113Stomach Neoplasms 106Neoplasm Metastasis 88Neoplasms 74Esophageal Neoplasms 59Small Cell Lung Carcinoma 44Neuroblastoma 42Lung Neoplasms 42Glioblastoma 38Carcinoma, Non-Small-Cell Lung 37Esophageal Squamous Cell Carcinoma 33Brain Neoplasms 33Unspecified Adult Solid Tumor, Protocol Specific 31Glioma 31Breast Neoplasms 28Central Nervous System Neoplasms 27Adenocarcinoma Of Esophagus 27Sarcoma 26Gliosarcoma 22Astrocytoma 22Rhabdomyosarcoma 21Sarcoma, Ewing 18Adenocarcinoma 18Gastrointestinal Neoplasms 17Oligodendroglioma 16Cholangiocarcinoma 14Recurrence 13

Interventions

Injections 3Fluorouracil 2Cisplatin 2toripalimab 1spartalizumab 1pembrolizumab 1SHR-1701 1Paclitaxel 1Oxaliplatin 1Irinotecan 1Gemcitabine 1Drug Therapy 1Docetaxel 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Malignant Tumors × Irinotecan × Clear all
NCT05235542 2022-08-11

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Akeso

Phase 1/2 Unknown
130 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡